BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19735087)

  • 1. Rasagiline-induced spontaneous ejaculation.
    Chuang RS; Lang AE
    Mov Disord; 2009 Oct; 24(14):2160-1. PubMed ID: 19735087
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety of rasagiline in elderly patients with Parkinson disease.
    Goetz CG; Schwid SR; Eberly SW; Oakes D; Shoulson I;
    Neurology; 2006 May; 66(9):1427-9. PubMed ID: 16682679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rasagiline. A new monoamine oxidase b inhibitor for Parkinson treatment].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2005 Jul; 28(7):224-7. PubMed ID: 16038119
    [No Abstract]   [Full Text] [Related]  

  • 4. MAO-B inhibitor know-how: back to the pharm.
    Lewitt PA
    Neurology; 2009 Apr; 72(15):1352-7. PubMed ID: 19365057
    [No Abstract]   [Full Text] [Related]  

  • 5. Rasagiline in Parkinson's disease: the show must go on.
    Jost WH
    Expert Opin Drug Saf; 2013 Nov; 12(6):797-800. PubMed ID: 23909684
    [No Abstract]   [Full Text] [Related]  

  • 6. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group
    Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The monoamine oxidase type B inhibitor rasagiline in the treatment of Parkinson disease: is tyramine a challenge?
    Chen JJ; Wilkinson JR
    J Clin Pharmacol; 2012 May; 52(5):620-8. PubMed ID: 21628600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoamine oxidase inhibitors--is it time to up the TEMPO?
    Rascol O
    Lancet Neurol; 2003 Mar; 2(3):142-3. PubMed ID: 12849233
    [No Abstract]   [Full Text] [Related]  

  • 10. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rasagiline as a therapy for Parkinson's disease (PD).
    Hermanowicz N
    Am J Geriatr Pharmacother; 2007 Jun; 5(2):174-5; author reply 175-6. PubMed ID: 17719520
    [No Abstract]   [Full Text] [Related]  

  • 12. Rasagiline: a guide to its use in Parkinson's disease.
    Keating GM; Lyseng-Williamson KA; Hoy SM
    CNS Drugs; 2012 Sep; 26(9):781-5. PubMed ID: 22834567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rasagiline. Parkinson's disease: a simple me-too.
    Prescrire Int; 2006 Dec; 15(86):220. PubMed ID: 17167927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa.
    Rabey JM; Sagi I; Huberman M; Melamed E; Korczyn A; Giladi N; Inzelberg R; Djaldetti R; Klein C; Berecz G;
    Clin Neuropharmacol; 2000; 23(6):324-30. PubMed ID: 11575866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comorbid states in Parkinson's disease: an effect of MAO-B inhibitors].
    Titova NV; Katunina EA; Sotnikova NN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(4):90-99. PubMed ID: 27386592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rasagiline: a review of its use in the management of Parkinson's disease.
    Oldfield V; Keating GM; Perry CM
    Drugs; 2007; 67(12):1725-47. PubMed ID: 17683172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rasagiline in Parkinson's disease.
    Chahine LM; Stern MB
    Int Rev Neurobiol; 2011; 100():151-68. PubMed ID: 21971007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline.
    Degli Esposti L; Piccinni C; Sangiorgi D; Nobili F; Buda S
    Neurol Sci; 2016 Feb; 37(2):227-34. PubMed ID: 26474874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment.
    Wilson RE; Seeberger LC; Silver D; Griffith A; Conner JB; Salzman PM;
    Neurologist; 2011 Nov; 17(6):318-24. PubMed ID: 22045282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rasagiline. Teva Pharmaceutical.
    Kupsch A
    Curr Opin Investig Drugs; 2002 May; 3(5):794-7. PubMed ID: 12090555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.